<?xml version='1.0' encoding='utf-8'?>
<document id="27777713"><sentence text="Medication Error When Switching from Warfarin to Rivaroxaban Leading to Spontaneous Large Ecchymosis of the Abdominal and Chest Wall."><entity charOffset="37-45" id="DDI-PubMed.27777713.s1.e0" text="Warfarin" /><entity charOffset="49-60" id="DDI-PubMed.27777713.s1.e1" text="Rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.27777713.s1.e0" e2="DDI-PubMed.27777713.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27777713.s1.e0" e2="DDI-PubMed.27777713.s1.e1" /></sentence><sentence text="Non-vitamin K oral anticoagulant (NOAC) therapy may be inappropriate if prescription was incorrect, the patient's physiological parameters change, or interacting concomitant medications are erroneously added"><entity charOffset="4-13" id="DDI-PubMed.27777713.s2.e0" text="vitamin K" /></sentence><sentence text=" The aim of this report was to illustrate inappropriate NOAC prescription in a 78-year-old woman with non-valvular atrial fibrillation and borderline renal dysfunction who was switched from warfarin to rivaroxaban and subsequently developed bruising with hemorrhagic shock and acute on chronic renal failure"><entity charOffset="202-213" id="DDI-PubMed.27777713.s3.e0" text="rivaroxaban" /></sentence><sentence text=" Administration of 4-factor prothrombin complex concentrate effectively reversed coagulopathy and stopped bleeding" /><sentence text=" Retrospective determination of circulating plasma levels of rivaroxaban and warfarin confirmed that excessive anticoagulation was likely due to warfarin that the patient probably continued to take although rivaroxaban was initiated"><entity charOffset="61-72" id="DDI-PubMed.27777713.s5.e0" text="rivaroxaban" /><entity charOffset="77-85" id="DDI-PubMed.27777713.s5.e1" text="warfarin" /><entity charOffset="207-218" id="DDI-PubMed.27777713.s5.e2" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.27777713.s5.e0" e2="DDI-PubMed.27777713.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27777713.s5.e0" e2="DDI-PubMed.27777713.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27777713.s5.e0" e2="DDI-PubMed.27777713.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27777713.s5.e1" e2="DDI-PubMed.27777713.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27777713.s5.e1" e2="DDI-PubMed.27777713.s5.e2" /></sentence><sentence text=" Pharmacodynamic interaction between rivaroxaban and warfarin may not only be additive but synergistic"><entity charOffset="37-48" id="DDI-PubMed.27777713.s6.e0" text="rivaroxaban" /></sentence><sentence text=" In patients at high risk of complications, judicious prescribing and dosing of NOACs, and regular monitoring of concomitant medications and renal function are highly recommended" /><sentence text="" /></document>